Member Info for dafad

Could be these being sold?

18 July 2025

Solvonis Therapeutics plc

("Solvonis" or the "Company")

Exercise of warrants

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, announces that the Company has received a notice to exercise warrants over 20,000,000 new ordinary shares of £0.001 each in the Company (the "Warrant Shares") at an exercise price of £0.001 per Warrant Share, raising £20,000 of new funds for the Company.

I would add to that -they are waiting for the warrants to clear for max share price impact

She might not mean it in this tweet but I will not be suprised that one day they will be riningvthe bell atvthe Nyse!

Could she mean the Avacta team will be rining the bell at the NYSE!!

Just gone through-news later or tomorrow!!

PUBLIC DOMAIN.

10 March 2026

Solvonis Therapeutics plc

("Solvonis" or the "Company")

SVN-114 selected as the lead candidate for PTSD discovery programme

Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery programme targeting Post-Traumatic Stress Disorder ("PTSD"), a condition affecting more than 20 million people worldwide for which effective pharmacological treatment options remain limited.

The selection follows compelling pharmacology results from preclinical studies conducted by Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT), in which SVN-114 demonstrated balanced modulation of serotonin ("SERT"), dopamine ("DAT") and noradrenaline ("NET"), key brain chemicals involved in mood, emotion and social behaviour.

Following review of the pharmacology data, the Company's Scientific Advisory Committee, led by Professor David Nutt, agreed to designate SVN-114 as the programme's lead candidate, marking an important milestone for Solvonis' proprietary CNS discovery platform.

Mechanism designed to support therapeutic engagement

The SVN-SDN-14 series is a class of serotonin ("SERT"), dopamine ("DAT") and noradrenaline ("NET") modulators designed to enhance pro-social behaviour and improve therapeutic outcomes for people living with PTSD..

By modulating neurochemical pathways associated with trust, empathy and social bonding, compounds in this series, including SVN-114, are intended to help patients rebuild interpersonal relationships and engage more effectively in therapy.

Novel chemistry supported by international patent applications

SVN-114 originates from a proprietary chemical series discovered through Solvonis' internal research programme. Composition-of-matter patent applications have been filed internationally covering both the compound class and its pharmaceutical applications.

The Company believes the intellectual property associated with this compound series provides a strong foundation for the development of first-in-class or best-in-class therapeutics targeting trauma-related psychiatric disorders in area of significant unmet clinical need and growing market demand.

Professor David Nutt, Chief Scientific Officer of Solvonis, commented: "The identification of SVN-114 as the lead candidate from this compound series represents an important step forward for the programme.

"The compound has demonstrated a robust pharmacological profile across serotonin, dopamine and noradrenaline systems in both in vitro and in vivo testing. These neurotransmitter systems are central to the neurobiology of trauma and social

I'm not sure but ar Temu new partnersthere are a few others that I gave not noticed before eurocarparts.please correct me if i am wrong

Https://www.londonstockexchange.com/news-article/market-news/vault-ventures-and-whitespace-develop-post-quantum-secure-communications-platform/17492952

MKANGO SUBSIDIARY, HYPROMAG, COMMISSIONS SECOND UK INSERMA UNIT FOR RAPID AUTOMATED PRE-PROCESSING OF HARD DISK DRIVES AND RECYCLING OF RARE EARTHS AND PRECIOUS METALS

London / Vancouver: March 9, 2026 - Mkango Resources Ltd. (AIM/TSX-V: MKA) ("Mkango") is pleased to announce that HyProMag Limited ("HyProMag") has successfully commissioned a second automated hard disk drive ("HDD") pre-processing unit in the UK, co-located at the recently opened commercial scale magnet recycling and manufacturing facility at Tyseley Energy Park, Birmingham.

Highlights:

· Cutting-edge technology developed and manufactured by HyProMag partner, Inserma Anoia S.L. ("Inserma"), to separate the magnet and printed circuit board assemblies (PCBA) from HDDs in seconds

· As part of the commissioning phase, a batch of 13,000 HDDs is being processed at Tyseley, with potential for one unit to process more than 30,000 HDDs per week on a single shift once fully commissioned

· The separated magnet assemblies from the HDDs will be processed via the patented Hydrogen Processing of Magnet Scrap (HPMS) technology being commercialised by HyProMag, and the PCBAs will be sold for precious metals recovery

· Low-cost sustainable automated solution, maximising potential value recovery and recyclability of critical elements in the HDD

The technology is being rolled-out into multiple jurisdictions with partners, Inserma, Intelligent Lifecycle Solutions Limited ("ILS") and CoTec Holdings Limited ("CoTec"), with further units already delivered for commissioning at HyProMag GmbH's facility in Pforzheim, Germany, and to HyProMag USA as per the following press release: HyProMag USA advances US Hub & Spoke Strategy

William Dawes, Chief Executive of Mkango and Director of HyProMag commented: "This is the second groundbreaking technology to be brought to commercial scale by HyProMag and its partners. Complementary to the HPMS technology being commercialised in the UK, Germany and USA, the Inserma technology unlocks a burgeoning source of NdFeB feedstock from HDDs, geared to large-scale data centre deployment on a global scale which is expected to be a major source of end-of-life HDDs. A five times growth in data centres is expected in Europe alone."

Nick Mann, Managing Director of HyProMag Ltd commented: "With millions of HDDs reaching end of life every year at data centres across the UK, the opportunity to recover critical materials is obvious. With PCBA separation, magnet separation and the centre spindle removal, the Inserma technology not only enables material recovery but also enhances data destruction processes and can even lower those costs. So, with critical material recovery, value add, improved sustainability and lower operating costs for data destruction, this is a rare case where all stakeholders can share the benefits."

Paco Ortiz, Director of Inserma commented: "We have a longstanding working relationship with HyProMag, Uni

We should know their rare esrths recycling plans by April

https://rareearthexchanges.com/news/japan-moves-to-secure-recycled-critical-minerals-as-supply-risks-rise-but-its-a-steep-climb/

/03/2026

Vault Ventures PLC

(the “Company” or “Vault”)

Vault Ventures Shares Commence Trading on U.S. OTCQB Market

Vault Ventures PLC (AQSE: VULT) is pleased to announce that its ordinary shares have commenced trading on the OTCQB Venture Market in the United States under the ticker “ VQESF ”.

The OTCQB quotation provides Vault Ventures with expanded access to U.S. capital markets, enabling U.S. investors and broker-dealers to trade the Company’s shares more efficiently. The additional quotation is intended to broaden the Company’s international investor base and increase visibility among North American investors.

The Company will continue to maintain its primary listing on the AQSE Growth Market under the ticker “VULT”, with the OTCQB quotation operating as a complementary U.S. trading venue.

Strengthening Access to the U.S. Investor Market

The OTCQB Venture Market is designed for early-stage and growth companies seeking to make their securities more accessible to U.S. investors through a recognised public market platform.

The cross-trading facility is expected to:

- Provide U.S. investors with easier access to Vault Ventures’ shares

- Increase the Company’s visibility within North American capital markets

- Support long-term shareholder value through improved international liquidity and market reach

No new shares are being issued in connection with this cross-trading facility. Vault Ventures will continue to adhere to its primary regulatory and reporting obligations on the Aquis Stock Exchange in the United Kingdom.

Exercise of Warrants

The Company also announces that it has received notice from a warrant holder to exercise warrants over a total of 10,000,000 ordinary shares of £0.01 each in the Company (“Ordinary Shares”) at an exercise price of 1p per Ordinary Share, raising £100,000 of gross proceeds.

The warrants were issued as part of the Company’s previous fundraising. The warrant exercise reflects continued support from existing investors who participated in that financing and provides additional working capital to support the Company’s continued development.

Altona (LSE: REE), a resource exploration and development company focused on critical raw materials in Africa, is pleased to announce an exercise of warrants over ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares").

Exercise of Warrants

The Company is pleased to announce that it has received Notices of Exercise from existing shareholders in respect of 4,200,000 warrants at an exercise price of 2.0 pence per Ordinary Share ("2p Warrants").

Accordingly, a further 4,200,000 new Ordinary Shares will be issued pursuant to these exercises.

This exercise of the 2p Warrants brings in further cash funds of £84,000, which will be used to fund the fluorspar and gallium resource estimate and scoping study.

Admission and Total Voting Rights

The 2p Warrants are being issued from authorities granted to directors to issue new Ordinary Shares at the annual general meeting of the Company's shareholders on 26 November 2025.

Application is being made for the New Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 6 March 2026. Following this issue of a further 4,200,000 new Ordinary Shares, which will rank pari passu with the Company's existing Ordinary Shares, the Company's enlarged share capital and total voting rights in the Company will comprise 378,882,301. The Company has no shares held in Treasury.

This figure of 378,882,301 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019.

This is too much of a coincidence imho,it's either a partnership or a full takeover imho

https://www.thomasnet.com/insights/mp-materials-rare-earth-magnet-texas-plant/

Just shown up-some from last Friday

02-Mar-26 16:26:35 3.6798 270,294 Unknown* 9,946 O

02-Mar-26 16:26:19 3.6674 200,000 Unknown* 7,335 O

02-Mar-26 16:23:55 3.6783 250,000 Unknown* 9,196 O

02-Mar-26 16:22:21 4.067 291,006 Unknown* 11.84k O

27-Feb-26 12:32:53 3.8111 600,000 Unknown* 22.87k O

27-Feb-26 16:20:15 3.80 1,900,000 Unknown* 72.20k O

27-Feb-26 15:47:49 3.86 558,111 Unknown* 21.54k O

27-Feb-26 12:52:15 3.63 1,200,000 Unknown* 43.56k O

27-Feb-26 12:30:09 3.55 1,633,333 Unknown* 57.98k O

27-Feb-26 12:29:56 3.55 3,366,667 Unknown* 119.52k O

27-Feb-26 11:50:40 3.795 750,000 Unknown* 28.46k O

27-Feb-26 08:43:17 3.495 600,000 Unknown* 20.97k O

27-Feb-26 12:39:32 3.64251 855,223 Unknown* 31.15k O

27-Feb-26 08:10:09 3.625 1,000,000 Unknown* 36.25k O

02-Mar-26 16:02:03 3.655 205,294 Unknown* 7,503 O

02-Mar-26 16:28:12 3.70 500,000

02 March 2026

Vault Ventures PLC

Vault Ventures PLC Appoints Andrew Webber to Strengthen Institutional and Blue-Chip Commercial Execution of Post-Quantum Strategy

Vault Ventures PLC ("Vault" or the "Company") is pleased to announce the appointment of Andrew Webber as Strategic Adviser, supporting the Board in accelerating institutional and blue-chip commercial adoption of its post-quantum security strategy.

Andrew is a commercial operator with vast experience across financial services and technology, with a track record of turning complex products into scalable enterprise revenue. He began his career in asset finance with US banking group CIT, where he built and launched white-label financing programmes for global technology customers including Dell, Cisco and Avaya, leading cross-border teams across the UK and Ireland.

He later held senior leadership roles within ABN AMRO's capital markets business and at Microsoft Financing, where a channel-led strategy contributed to rapid revenue growth and earned a Global Leadership Award. Across these roles, Andrew worked directly within regulated banking and enterprise environments, structuring commercial programmes that aligned technology deployment with procurement, compliance and risk frameworks.

Vault's refined strategy is centred on post-quantum encryption and long-duration security infrastructure designed for regulated institutional deployment. Execution in this market requires credibility with banking institutions, alignment with enterprise infrastructure standards and disciplined commercial structuring, not simply technical capability.

Andrew's experience commercialising technology within financial services and blue-chip enterprises directly supports this next phase. In his advisory capacity, he will provide input on institutional engagement strategy, commercial positioning within regulated sectors and the progression of post-quantum initiatives from pilot programmes to production adoption.

Andrew currently serves as Chief Partnerships Officer at Whitespace, a UK-based sovereign AI company delivering secure enterprise-grade solutions within regulated and security-sensitive environments. He will continue in that role alongside his advisory position with Vault.

Brian Stockbridge, Chairman of Vault , commented:

"Our post-quantum strategy is focused squarely on institutional and regulated markets. Andrew's experience working with banking institutions and blue-chip enterprises strengthens our ability to execute commercially in environments where security, compliance and infrastructure alignment are critical."

Andrew Webber commented:

"Post-quantum security is becoming a structural requirement for regulated institutions and enterprise infrastructure providers. Successful deployment depends on disciplined commercial execution, integration into existing technology estates and alignment with procurement and governance frameworks. Vault's strategy reflects that realit

Wish I could hear what was being said-some photos as well if you slide

https://www.instagram.com/steph__escobar/p/DVOor8KDv6j/?img_index=10

Nm

Add to that circa 700k from the warrants excersised thi last few weeks

Alignment with US strategic priorities represents a transformative step for Altona. We expect this collaboration to deepen over the life of the project, complementing our recent initiative to position the Company on North American capital markets through our application to trade on the OTCQB."

Strategic Partnership and Funding

Under the terms of the Agreement, USTDA will provide a grant of US$ 1,875,000 to fund the metallurgy and process engineering components of the Monte Muambe rare earths prefeasibility study.

The funded program will include:

· A targeted drilling campaign to obtain representative metallurgical samples

· Comprehensive metallurgical testing and engineering studies covering comminution, beneficiation and hydrometallurgy, including the separation of NdPr oxide from mixed rare earth carbonate

· Associated environmental and commercial studies

· Engagement with potential US off-take partners

· The development of an updated financial model

The grant fully funds these critical de-risking workstreams, which will run in parallel with the on-going development of the Company's high-grade fluorspar deposits. Selection of the contractor(s) to undertake the funded work will commence in due course.

Strengthening Critical Mineral Supply Chains

Thomas R. Hardy, USTDA's Deputy Director, commented: "Securing access to rare earths is essential for America's defense industrial base and our technological edge. By partnering on the Monte Muambe project, we're advancing both countries' strategic priorities: strengthening U.S. supply chain security while supporting Mozambique's goal of becoming a major player in the global critical minerals market."

Cedric Simonet, CEO, commented: "The USTDA grant represents more than just non-dilutive funding - it is a tangible operational partnership and a powerful strategic endorsement. Working with the US Government through USTDA significantly advances the Company's ambition to become a major, responsible Western source of magnet rare earths.

"Alignment with US strategic priorities represents a transformative step for Altona. We expect this collaboration to deepen over the life of the project, complementing our recent initiative to position the Company on North American capital markets through our application to trade on the OTCQB."

​

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019.

-ends-